Co-Diagnostics Posts $46.9M Loss in 2025 Amid Grant Revenue Drop and Asset Impairment

Event summary

  • Co-Diagnostics reported a net loss of $46.9 million in 2025, up from $37.6 million in 2024, driven by a $18.9 million non-cash impairment charge and a 95% drop in grant revenue.
  • Revenue fell to $0.6 million from $3.9 million in 2024, with operating expenses rising to $50.6 million from $43.0 million.
  • The company raised $10.8 million through two stock offerings in 2025, selling shares at $0.40 and $0.55 per share on a pre-reverse split basis.
  • Co-Diagnostics secured a CDSCO license to manufacture and sell the PCR Pro® instrument in India, expanding its commercial territory to include Bangladesh, Pakistan, Nepal, and Sri Lanka.
  • The company initiated shipments of PCR Pro® instruments and tuberculosis (TB) test materials to India for upcoming clinical performance studies.

The big picture

Co-Diagnostics is navigating a challenging financial landscape, marked by significant revenue declines and rising operating expenses. The company's strategic focus on expanding its global footprint through joint ventures and securing regulatory approvals for its PCR platform is critical for its long-term viability. The diagnostics sector continues to evolve, with a growing emphasis on AI integration and regulatory compliance, which Co-Diagnostics is addressing through its Primer Ai™ platform and clinical evaluations.

What we're watching

Regulatory Milestones
The pace at which Co-Diagnostics advances its FDA 510(k) submission for the upper respiratory test focused on flu A, flu B, and RSV will determine its commercialization timeline.
Market Expansion
Whether Co-Diagnostics can successfully execute its joint ventures in India and Saudi Arabia to tap into the $13 billion regional addressable market.
Financial Sustainability
How the company will manage its cash position, which fell to $11.9 million by the end of 2025, amid ongoing operating losses.

Related topics

Diagnostics